Surgery for Cardiac Valve Disease

2020 ◽  
pp. 570-576
Keyword(s):  
Cardiac Valve ◽  
Valve Disease ◽  
Cardiac Valve Disease

Abstract MP235: PROX1 Contributes To Cardiac Valve Disease

2021 ◽  
Vol 129 (Suppl_1) ◽  
Author(s):  
YenChun Ho ◽  
Xin Geng ◽  
Rohan Varshney ◽  
Jang Kim ◽  
Sandeep Surbrahmanian ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Heart Valves ◽  
Cardiac Valve ◽  
Valve Disease ◽  
Matrix Composition ◽  
Cardiac Valves ◽  
Aortic Valves ◽  
Mitral Valves ◽  
Valve Development ◽  
Cardiac Valve Disease

Background: Heart valves regulate the unidirectional forward flow and prevent retrograde backflow of blood during the cardiac cycle. Cardiac valve disease (CVD) is observed in approximately 2.5% of the general population and the incidence increases to ~10% in elderly people. Patients with severe CVD require surgery and effective pharmacological treatments are currently not available. PROX1 is a transcription factor that regulates the development of lymphatic, venous, and lymphovenous valves (vascular valves). We identified that PROX1 is also expressed in a subset of valvular endothelial cells (VECs) that are located on the downstream (fibrosa) side of cardiac valves. Whether PROX1 regulates cardiac valve development and disease is not known. Method and Results: We have discovered that mice lacking Prox1 in their VECs ( Prox1 ΔVEC ) develop enlarged aortic and mitral valves in which the expression of proteoglycans is increased (control, N=10; Prox1 ΔVEC , N=9, p <0.05). Echocardiography revealed moderate to severe stenosis of aortic valves of Prox1 ΔVEC mice (control, N=5; Prox1 ΔVEC , N=9, p <0.05). PROX1 regulates the expression of the transcription factor FOXC2 in the vascular valves. Similarly, we have found that the expression of FOXC2 is downregulated in the VECs of Prox1 ΔVEC mice. Specific knockdown of FOXC2 in VECs results in the thickening of aortic valves (control, N=10; shFoxc2 ΔVEC , N=8, p <0.05). Furthermore, restoration of FOXC2 expression in VECs ( Foxc2 OE-VEC ) ameliorates the thickening of the aortic valves of Prox1 ΔVEC mice ( Prox1 ΔVEC , N=9; Foxc2 OE-VEC ; Prox1 ΔVEC , N=8, p <0.05). We have also determined that the expression of platelet-derived growth factor-B ( Pdgfb ) is increased in the valve tissue of Prox1 ΔVEC mice and in PROX1 deficient sheep mitral valve VECs (MVECs) (siCtrl , N=4; siProx1 , N=4, p <0.05). Additionally, hyperactivation of PDGF-B signaling in mice results in a phenotype that is similar to Prox1 ΔVEC mice (control , N=4; Pdgfb GOF , N=3, p <0.05). Conclusion: Together these data suggest that PROX1 maintains the extracellular matrix composition of cardiac valves by regulating the expressions of FOXC2 and PDGF-B in VECs.

scholarly journals Cost of diseases in Brazil: breast cancer, enteritis, cardiac valve disease and bronchopneumonia

1995 ◽  
Vol 29 (5) ◽  
pp. 349-354 ◽  
Author(s):  
Armando Arredondo ◽  
Lejeune Y. Lockett ◽  
Esteban de Icaza
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Cost Analysis ◽  
Economic Cost ◽  
Cardiac Valve ◽  
Valve Disease ◽  
Use Of Resources ◽  
Economic Cost Analysis ◽  
Cardiac Valve Disease ◽  
Support Decision Making

The results from the need to develop methodologies for performing cost analysis in developing countries, principally in the region of Latin America, were studied. It, furthermore, serves to generate knowledge from an economic evaluation in order to support decision-making related to the organization of health systems, particularly in the efficient use of resources which are allocated for the provision of medical services. Two chronic diseases (breast cancer and cardiac valve disease) and two infections (enteritis and bronchopneumonia) were selected for the study. The results recommend the use of a valid methodology for economic cost analysis of any disease to be studied and the use of this information in the decision-making process.

Cardiac valve disease

2014 ◽  
pp. 96-96
Author(s):  
Sara-Catrin Cook ◽  
Matt Thomas ◽  
Jerry Nolan ◽  
Michael Parr
Keyword(s):  
Cardiac Valve ◽  
Valve Disease ◽  
Cardiac Valve Disease

Diet Drug-Related Cardiac Valve Disease: The Mayo Clinic Echocardiographic Laboratory Experience

2000 ◽  
Vol 75 (5) ◽  
pp. 456-461 ◽  
Author(s):  
Chari Y. Teramae ◽  
Heidi M. CONNOLLY ◽  
Martha Grogan ◽  
Fletcher A. Miller
Keyword(s):  
Mayo Clinic ◽  
Cardiac Valve ◽  
Valve Disease ◽  
Laboratory Experience ◽  
Cardiac Valve Disease

Cardiac Valve Disease in Children

1988 ◽  
Vol 63 (2) ◽  
pp. 215-216
Author(s):  
Douglas D. Mair
Keyword(s):  
Cardiac Valve ◽  
Valve Disease ◽  
Cardiac Valve Disease

scholarly journals The effect of neonatal gene therapy with a gamma retroviral vector on cardiac valve disease in mucopolysaccharidosis VII dogs after a decade

2013 ◽  
Vol 110 (3) ◽  
pp. 311-318 ◽  
Author(s):  
Paul W. Bigg ◽  
Meg M. Sleeper ◽  
Patricia A. O'Donnell ◽  
Yuli Liu ◽  
Susan Wu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Retroviral Vector ◽  
Cardiac Valve ◽  
Valve Disease ◽  
Cardiac Valve Disease

A595 ACUTE MYOCARDIAL beta-ADERNERGIC RECEPTOR DESENSITIZATION DURING CARDIOPULMONARY BYPASS IN PATIENTS WITH CARDIAC VALVE DISEASE

1997 ◽  
Vol 87 (Supplement) ◽  
pp. 595A
Author(s):  
&NA; Gerhardt ◽  
L.C. Chesnut ◽  
B.L. Funk ◽  
K.P. Landolfo ◽  
D.A. Schwinn
Keyword(s):  
Cardiopulmonary Bypass ◽  
Cardiac Valve ◽  
Valve Disease ◽  
Receptor Desensitization ◽  
Cardiac Valve Disease
Sign in / Sign up

Export Citation Format

Share Document